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Abstract
Background: This work aimed to study the homing evidence and the reparative effect of mesenchymal stem cells
(MSCs) in the healing process of induced osteoarthritis in experimental animal model (donkeys).
Methods: Twenty-seven donkeys were equally divided into 3 groups based on the observation period after
induction of arthritis (3, 6 and 9 weeks) to achieve different degrees of osteoarthritis. Each group was subdivided
into three subgroups of three animals each based on the follow-up period (1, 2 and 6 months) after treatment.
The induction was done through intra-articular (IA) injection of 2 ml of Amphotericin-B in both carpal joints. MSCs
were harvested in a separate procedure, labeled with green fluorescent protein (GFP) using monster GFP vector
and suspended in hyaluronic acid for IA injection. Treatment approaches consisted of cell-treatment using MSCs
suspended in 3 ml of hyaluronic acid (HA) for the right carpal joint; and using the same amount of (HA) but
without MSCs for the left contralateral carpal joint to serve as a control. Animals were assessed clinically and
radiologically before and after treatment. Synovial fluid was also evaluated. Histopathologically; articular cartilage
structural changes, reduction of articular cartilage matrix staining, osteophyte formation, and subchondral bone
plate thickening were graded. Data was summarized using median and percentile for scores of histopathologic
grading. Comparison between groups was done using non-parametric Mann Whitney test.
Results: The reparative effect of MSCs was significant both clinically and radiologically in all treated groups (P <
0.05) compared to the control groups. Fluorescence microscopy of sections of the cell-treated joints of all animals
indicated that the GFP-transduced injected cells have participated effectively in the reparative process of the
damaged articular surface and have integrated within the existing articular cartilage. The cells were associated with
the surface of the cartilage and, were also detected in the interior.
Conclusions: Homing was confirmed by the incorporation of injected GFP-labeled MSCs within the repaired newly
formed cartilage. Significant recovery proves that the use of IA injection of autologous MSCs is a viable and a
practical option for treating different degrees of osteoarthritis.
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Background
Adult marrow-derived Mesenchymal Stem Cells (MSCs)
are capable of dividing and their progeny are further
capable of differentiating into one of several mesenchy-
mal phenotypes such as osteoblasts, chondrocytes,
myocytes, marrow stromal cells, tendon-ligament fibro-
blasts, and adipocytes. In addition, these MSCs secrete a
variety of cytokines and growth factors that have both
paracrine and autocrine activities. These secreted bioac-
tive factors suppress the local immune system, inhibit
fibrosis (scar formation) and apoptosis, enhance angio-
genesis, and stimulate mitosis and differentiation of tis-
sue-intrinsic reparative or stem cells. These trophic
effects are distinct from the direct differentiation of
MSCs into repair tissue [1].
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city of these cells to home and engraft long-term into
the appropriate target tissue [2]. MSC therapy has been
applied in bone and cartilage repair and in the treat-
ment of osteoarthritis [3].
Osteoarthritis (OA), the most common form of joint
disease, is characterized by degeneration of the articular
cartilage and, ultimately, joint destruction [4]. Loss of
articular cartilage; caused by mechanical and oxidative
stresses, aging or apoptotic chondrocytes; provoke syno-
vial lining cells and articular chondrocytes within dis-
eased cartilage to synthesize and secrete proteolytic
enzymes, such as matrix metalloprotinases (MMP),
aggrecanases, proinflammatory cytokines and mediators
such as nitric oxide and prostaglandins which degrade
the cartilaginous matrix [5,6].
Despite the high prevalence and morbidity of osteoar-
thritis (OA), an effective treatment is currently lacking.
Restoration of the diseased articular cartilage in patients
with OA is the challenge [4]. Difficulties in studying
osteoarthritis in humans that stem from both the low sen-
sitivity of diagnostic tools and the low availability of dis-
eased tissues explain why research on animal models
remains highly dynamic. Several animal models have been
studied. Animal models of osteoarthritis (OA) include
spontaneous models in aging animals, genetically modified
mice, as well as surgically, enzymatically or chemically
induced models [7]. IA injection of Amphotericin-B con-
sistently resulted in aseptic arthritis in horses [8-14].
In clinical settings, the optimal route for administration
of stem cells depends on the anatomy and the extent of
damage of the involved tissue or organ, offering a choice
between two approaches: direct local or intralesional
implantation versus systemic intravascular administration.
Site-directed delivery of MSCs has shown their engraft-
ment in several tissues, particularly after injury. Several
research work have discussed the use of bone marrow
cells to repair infarcted myocardium [15,16], repair of
spinal cord injuries [17-19] and in treatment of large carti-
lage defects [4]. As a result, cartilage repair with direct
intra-articular injection (IA) of MSCs has been proposed
as a potential cell therapy in a model of OA [20,21].
This work aimed to study the homing evidence and
the reparative effect of intra-articularily injected
mesenchymal stem cells (MSCs) in the healing process
of experimentally-induced animal model (donkeys) of
osteoarthritis having different degrees of osteoarthritis
(mild, moderate and severe) and followed up for 1, 2
and 6 months after treatment.
Methods
Study design
Induction of three different degrees of arthritis in
twenty-seven animals using the same technique
developed by [14]. Animals were equally divided into 3
groups (9 each) based on the observation period (3, 6
and 9 weeks). Each group was subdivided into three
subgroups (3 animals each) based on the follow up per-
iod (1, 2 and 6 months) after cell-treatment (Figure 1).
Bone marrow (BM) was harvested from each animals.
MSCs were identified, labeled with green fluorescent
protein (GFP) and suspended in hyaluronic acid for I.A.
injection. Each animal received a single shot of autolo-
gous cell-treatment (MSCs suspended in Hyaluronic
acid) in the right carpal joint. The left carpal joint
served as a control and received hyaluronic acid only.
Animals were assessed clinically; before and after treat-
ment. Radiological, Synovial fluid analysis and histo-
pathological assessment were performed.
1- Preparation of experimental animal model and Induction
of arthritis
This animal experiment followed the guidelines devel-
oped by the American Psychological Association (APA)
for the ethical conduct of care and use of animals [22]
and approval was obtained from the faculty of Veterin-
ary medicine, Cairo University, Egypt. All animals were
prepared in the same manner. Mild, moderate and
severe degrees of arthritis were achieved 3, 6 and 9
weeks respectively after IA injection of 2 ml of Ampho-
tericin-B 50 mg (Fungisone 50, 000 I.U.) in both carpal
joints of each animal [14].
2-Pre-treatment Follow-up
2.1-Clinical Assessment Evaluation of lameness was
done following the American Association of Equine
Practitioners (AAEP) scale for lameness evaluation [23];
(0 = Sound; 1 = Lameness difficult to detect and incon-
sistent; 2 = Lameness difficult to detect, but consistent;
3 = Lameness consistently detectable on a straight line;
4 = Obvious lameness with marked head nodding).
2.2-X-Ray filming X-ray films of the carpal joints were
taken prior to any interference. The settings of the x-ray
machine and the degree of arthritic changes were scored
using a modified [9]. The score ranged from0 to 4 scale
(Table 1). Radiographs were taken before induction
(injection of amphotericin B), of each carpus for each
animal, and on experimental days 0, and weekly
afterwards.
2.3-Synovial Fluid Synovial fluid was aspirated in a
sterile syringe for analysis. Synovial analysis, included:
physical properties (color, viscosity), Biochemical para-
meters: alkaline phosphatase (ALK), aspartate amino-
transferase (AST), Alanine aminotransferase (ALT)
Lactic acid dehydrogenase (LDH), and total proteins
(TP) together with cytological analysis [14]. Animals
were securely controlled, casted laterally. Two samples
from each carpal joint were collected from each animal,
immediately prior to MSCs injection (post-induction)
and at the time of sacrifice (post-treatment).
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Page 2 of 183- Acquisitions of Bone Marrow
Four weeks before any cell-treatment, bone marrow
samples were taken from the lateral side of the proximal
portion of the humerus bone, from the area below the
head of the humerus and above the trochanter major.
Animals were anaesthetized and securely controlled on
lateral recumbency. The hair on the shoulder region was
clipped, shaved and the area was disinfected with chlor-
ohexidine then touched with Bovidone Iodine prepara-
tion. A bone marrow needle 14 G (2.0) was used to
reach the bone marrow cavity after being moistened
with Heparin Sterile syringe of was used to aspirate 20
cc of the bone marrow on 2 cc of 1500 IU of Heparin.
4- Laboratory work: Preparation of mesenchymal stem cells
The lab work consisted of three major steps: Isolation;
characterization; culturing and labeling of MSCs.
4.1-Isolation of MSCs Under complete aseptic techni-
que; the isolation of MSCs was performed [24]. The
bone marrow aspirate was diluted 1:3 with stromal med-
ium consisting of DMEM-Ham’s F12 medium (vol/vol,
1:1; HyClone, Logan, UT), layered onto Histopaque-
1077 (Sigma, St Louis, MO, USA) and centrifuged at
400 g for 30 min. The collected buffy coat was mixed
with 20 ml of Dulbecco’s phosphate-buffered saline
(DPBS) and centrifuged at 300 g for 5 min. The super-
natant was discarded and the cells pellet was washed
two more times with DPBS. After determination of cell
viability and the number of viable cells by trypan blue
staining, the washed pellet cells was re-suspended in
DMEM-Ham’s F12 medium (Sigma) supplemented with
10% fetal bovine serum (FBS; USDA, Gibco, Grand
Island, NY, USA), antibiotics (penicillin 10 000 U⁄ ml,
streptomycin 10 000 U ⁄ml) and Amphotericin-B 25 U⁄
ml. This medium was also used as a control medium for
the experiments. The nucleated cells were plated as pri-
mary culture in tissue culture flask at 2.5 × 10
5⁄cm
2 and
incubated at 37°C in a humidified atmosphere contain-
ing 5% CO2. On day 4 of culture, the non-adherent cells
were removed along with the change of medium every 2
days. Undifferentiated MSCs were transplanted in this
study upon reaching 70-80% confluence. The cells were
counted with a hemocytometer and resuspended in 3 ml
of hyaluronic acid at a final density of 1.8-2.3 × 10
6cells/
ml prior to intra-articular injection.
4.2-In vitro Characterization of MSCs Cells were iden-
tified as being MSCs by their morphology; the adherent
colonies of spindle fibroblast like- cells were trypsinized,
and counted. MSCs phenotypes were confirmed by flow
cytometry and analysis of cell surface molecules as
detailed elsewhere [25] for CD34
- and CD29
+.C e l l s
were sorted by using FITC-labeled anti-CD34 (1:20;
DAKO, Carpinteria, CA, USA), and anti-CD29 (1:20;
DAKO). Briefly, after staining with appropriately conju-
gated antibodies (Ab) and washings, cells were analyzed
on a BDL cytofluorimeter, (BD Biosciences). The area of
positivity was determined using an isotype matched con-
trol Ab. 10
4 events for each sample were acquired. They
were also characterized by their in vitro power to differ-
entiate into osteocytes and chondrocytes [26]. For osteo-
genic induction, MSCs were plated at 2 × 10
4 cells/cm
2
Figure 1 Schematic diagram of the animal groups showing the induction of different degrees of arthritis with the following
observation period, then the treatment stage with the follow up period.
Table 1 Crawford Radiographic scoring system
Radiographic evaluation
0 = normal
1 = no bone or cartilage change, slight joint distention and effusion.
2 = minimal bone changes, osteophytes < 1 mm, without evidence of cartilage loss
3 = moderate bone changes, osteophytes 1- 2 mm, bone lysis or cartilage loss
4 = severe bone changes, osteophytes > 2 mm, with/without evidence of cartilage loss and/or bone lysis
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(DMEM supplemented with 10 mM b-glycerophosphate,
10-8 M dexamethasone, and 0.2 mM ascorbic acid) for
up to 20 days, with medium changed three times per
week. For chondrogenic induction, MSCs were pelleted
and cultured in chondrogenic differentiation medium
(DMEM supplemented with 0.1 μM dexamethasone,
0.17 mM ascorbic acid, 1.0 mM sodium pyruvate, and
0.01 μg/ml transforming growth factor-b (Peprotech,
London) for 28 days with medium changed three times
per week. The micromass pellets were formalin fixed,
paraffin embedded, and sectioned in slices. Thereafter,
in vitro differentiation into osteocytes and chondrocytes
was confirmed by alizarin red and alcian blue stains for
osteocytes and chondrocytes respectively in cells culture
pellet.
4.3-Labeling of MSCs Undifferentiated MSCs were har-
vested and were labeled with green fluorescent protein
(GFP) using monster green fluorescent protein vector
and lipofectamintransfast transfection reagent kit (Pro-
m e g a ,M a d i s o n ,W I ,U S A ) .B e f o r et r a n s f e c t i o n3-5×
10
5 cells were seeded into individual wells of 6 well-
plates. After 24 h incubation in growth medium, the
cells were exposed to 2 μg GFP plasmid/well of cells.
GFP plasmid was incubated with lipofectamin for 10-15
minutes before subjection to the cells. Following trans-
fection the cells were incubated at 37°C in humidified
air (5% CO2) for 2 h. The transfection medium was
then removed and the cells were incubated for an addi-
tional 48 h in complete medium (2 ml per well) [27].
For imaging GFP auto-fluorescence of MSCs, unstained
slides were directly analyzed by confocal laser micro-
scopy (LSM 510, Zeiss, Jena, Germany) incorporating
two lasers (Ar and HeNe) equipped with an inverted
Axiovert 100 M microscope [28].
5-Injection of MSCs
Based on the timetable provided (Additional file 1);
immediately following the aspiration of the synovial
fluid and at the same procedure, each animals received
its designated autologous MSCs IA injection coupled
with Hyaluronic acid on its right carpal joint, while the
left carpal joint was injected with Hyaluronic acid only.
6-Post-treatment follow-up
Clinical Assessment, X-Ray Filming and Synovial fluid
sample analysis were done in the same manner as the
pre-treatment assessment.
7- Sampling
At the end of the experiment, and according to the
sacrifice table, euthanasia was done. The skin was
removed from the carpi and transverse cuts were made
with a band saw through the radius just above the distal
epiphysis and through the metacarpal below the carpo-
metacarpal joint. The carpal canal was removed to allow
complete extension of the carpus. The carpus was then
opened at radio-carpal joint, metacarpal joint. The syno-
vial membrane and fibrous joint capsule could be exam-
ined. The cartilage surface of the bone, each cut, also,
was carefully examined.
8- Assessment of homing
For assessment of homing of MSCs, unstained paraffin-
embedded 4 μ m thick sections were examined by fluor-
escent microscope for detection of GFP-labeled stem
cells in the newly formed cartilage.
9-Histopathologic and Histochemical Assessment
Histologic assessment of the articular surface of the radio
carpal joints for all animals was done to determine if there
were differences between the MSCs-treated and untreated
groups. The pathologist was totally veiled from the sample
numbers and groups of this study. All cases were fixed in
10% neutral buffer formalin. De-calcification of tissue
cases were done by using 8% formic acid decalcifying solu-
tion in distilled water. The decalcifying solution was
renewed every 48 hours until softening of the tissues. The
decalcified specimens were then trimmed, washed and
dehydrated in ascending grades of alcohol, cleared in
xylene, embedded in paraffin, sectioned at 4-6 μm thick-
ness and stained with haematoxylene and eosin as well as
Masson’st r i c h r o m es t a i nf o rd e t e c t i o no fc o l l a g e nf i b e r s
and degree of matrix staining. Alcian Blue-PAS stain was
used for staining of the acidic glycosaminoglycans. The
appearance of the blue color in the areas of cartilage with
pathological morphology chemically indicates enrichment
of acidic glycosaminoglycans. Histologically it indicates
newly formed cartilaginous tissue [29].
10-Semiquantitative Histological Scoring
Articular cartilage structure, reduction of articular carti-
lage matrix staining, changes in osteophyte formation,
and subchondral bone plate thickening were graded
according to [20] as described in table 2.
10-Statistical Analysis
Data was coded and entered using statistical package
SPSS version 15. Data was summarized using median
and percentile for scores of histopathologic grading.
Comparison between groups was done using non para-
metric Mann Whitney test. P values less than or equal
to 0.05 were considered as statistically significant.
Results
I- Mesenchymal stem cell identification and
characterization
MSC identification and characterization was done by the
phenotypic analysis of the cells. Flow cytometric charac-
terization analyses of bone marrow-derived MSCs
showed that the cells were uniformly negative for CD34
and positive for CD29 (Figure 2).
Undifferentiated MSCs were identified in vitro by its
characteristic adhesive morphology (fibroblast like cell)
as labeled by arrows in Figure 3a. The ability of MSCs
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identified in vitro by changing their morphology as
labeled by arrows in Figure 3b, c and by their staining
with special staining as Alzarin red and Alcian blue for
differentiated cells respectively as shown (Figure 4).
II-Assessment before and after intra-articular GFP-labeled
MSCs
Cell-treated joints (right carpi) were assessed at pre- and
post-treatment with MSCs in hyaluronic acid and
compared with control joints (left carpi) treated only
with hyaluronic acid. Assessment results were:
II-1-Clinical lameness and swelling
Clinical signs in the form of acute swelling and joint
capsular distention began within the first 3 hours post
induction. The enlargement of the joint circumference
was evaluated to have an average increase of 1 ± 0.24
cm. In the control joint, lameness in group-I was diffi-
cult to detect and inconsistent (score 1) whereas in
group-II, lameness was difficult to detect, but consistent
Table 2 Histopathologic grading system
Parameter & Grade Description
Articular cartilage structure
0 - 10 (30) 0 = normal, 10 = complete loss to subchondral bone
Reduction of articular cartilage matrix staining
0 None
1 Mild
2 Moderate
3 Severe
Presence of osteophytes
0 None
1 Cartilage \ connective tissue
2 Mainly cartilage\ some bone formation
3 Mainly bone formation
Subchondral bone plate thickening
0 None
1 Mild
2 Moderate
3 Severe
Figure 2 Flow cytometric characterization analyses of bone marrow-derived MSCs. Cells were uniformly negative for CD34, and positive
for CD29.
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Page 5 of 18(score 2). In group-III, lameness was obvious with
marked head nodding (score 4). Joint stiffness detected
through visual inspection and passive bending of the
joint. Stiffness was mild at 1 month and moderate at 2
month follow-up periods. Marked joint stiffness was
clearly felt on examination in the left joints at 6 month
follow-up period in all groups.
After intra-articular injection of GFP-labeled MSCs, all
animals in all groups showed no improvement in
motion after 1 month of treatment. In group-I;
improvement was seen in animals kept for 2 and 6
months (score 1 and 0 respectively). Similarly, animals
in group-II; improvement was seen in animals lasted
for 2 and 6 months (score 2 and 1 respectively). Ani-
mals in group-III; showed improvement in animals
lasted for 2 and 6 months (score 4) as shown in the
table 3.
II-2. Radiological findings
Pre-injection of GFP-labeled MSCs: joints of all animals in
group-I (3 weeks of induction) were less affected and the
joint spaces were radiologically normal (score 0) whereas
those of group-II and group-III (6 and 9 weeks post-
induction respectively) showed narrowing of the joint
spaces (score 2) with moderate degree of bone lysis in
group-III (score 3). In the flexed view, thinning of the
articular surface was noticeable. The thinning degree was
higher in animals of group-III (score 4) than those of
group-I (score 0) or group-II (score 2) (Figures 5, 6 and 7).
Post-injection of GFP-labeled MSCs: in group-I, there
was no noticeable change in joint status in animals after
1 month of treatment. Joint were radiologically normal
(score 0) and improvement degree did not differ much
a t2a n d6m o n t hf o l l o wu p .I ngroup-II,t h e r ew a sn o
noticeable change in joint status in animals after 1
month of treatment (score 2). Joint improvement was
obvious after 2 months follow up (score 1). Improve-
ment degree did not differ much at 6 month follow up
(score 1). In group-III, no noticeable change in joint
status was recorded in animals after 1 or 2 months of
treatment (score 4). Mild joint improvement was seen
after 6 month follow up (score 3). Radiological scoring
of all animals was summarized in table 4.
II-3-Synovial fluid analysis
Physical, cytological and biochemical characteristics of
synovial fluid analysis according to [30] of all animal
models of OA are summarized in table (5 and 6) and
Figure 8.
II.4- Macroscopic appearance
Macroscopically, the articular surfaces showed different
arthritic changes varied from slight discoloration to
osteophytes formation. The magnitude of articular dis-
coloration, erosions and articular surface roughness was
higher in group-III than the other two groups (Figure
9a). The antebrachiocarpal joint after 2 months of OA
induction and 6 month of no treatment showed severe
articular surface degeneration affecting the carpal bones.
Figure 3 (a) MSCs-BM cells in culture without adding growth factors for osteogenic and chondrogenic differentiation arrows show
fibroblast-like cells in morphology. (b) MSCs-BM cells in culture after adding growth factors for osteogenic and (c) chondrogenic
differentiation arrows show change in MSCs morphology.
Figure 4 (a) Control undifferentiated MSCs showed neither staining with Alzarin red (special stain for differentiated MSCs into
osteoblasts) nor Alcian blue (special stain for differentiated MSCs into chondrocytes); (b) Osteogenic differentiation of these cells
shows the presence of alizarin stained calcium deposits in MSCs-BM; (c) Chondrogenic differentiation of MSCs-BM shows the presence
of Alcian blue stained of differentiated cells. All these images are at a magnification of 20X.
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damaged cartilage was observed (Figure 9b). Likewise, in
group-I the only noticeable changes were slight disco-
loration of the articular surface macroscopic where the
normal bluish-white surface has become yellowish in
color together with some capsulitis identified by pete-
chial hemorrhagic spots on the joint capsule (Figure 9c).
Slight differences could be noticed between the Cell-
treated joints and none-cell-treated ones (Figure 9d).
In moderate cases of group-II, discoloration, slight
erosions (Figure 9e) and slight roughness of the articular
surface existed. Cell-treated joints showed evidences of
better improvement than none-cell-treated ones (Figure
9f).
II-5.Microscopic hisopathology
In order to evaluate the possible changes between the
MSCs-treated and untreated groups, histological assess-
ment of the articular surface of the radio-carpal joint
from all animals was done using fluorescence micro-
scopy analysis of the cell-treated joints together with
regular and cartilage special dyes.
II-5.1.MSCs homing & florescence assessment
Fluorescence microscopy of sections of the cell-treated
joints of all groups indicated that the GFP-transduced
implanted cells were integrated with in the articular carti-
lage. The cells were associated with the surface of the car-
tilage and, were also detected in the interior (Figure 10).
II.5.2.Hiastopathological assessment
Reduction of articular cartilage matrix staining, changes,
osteophyte formation, and subchondral bone plate thick-
ening were graded as described in table 7 according to
[20] and results were as follows:
Group-I
Post- injection termination after 1 month
Animals in this group died before the date of assess-
ment and so were not histopathologically evaluated.
Post- injection termination after 2 months
Obvious difference was seen between control and treated
joints; Control joints showed fibrillation of 1/3 to 2/3 of
articular cartilage, prominent duplicated tide mark, clus-
ters of chondrocytes, calcification, and mild reduction of
matrix staining. And mild subchondral bone plate thick-
ening. Histopathologic scores were 9, 10, 10 (Figure 11a).
Treated joints: histologic scores for all parameters were
closer to normal in cell-treated joints, and treatment had
a significant effect on maintenance of the articular carti-
lage structure and subchondral bone plate thickening.
Histopathologic scores were 6, 6, 5 (Figure 11b).
Post-injection termination after 6 months
Control group There was hypocellularity, atrophic cells,
erosions and focal areas of bone eburnation, moderate
reduction of matrix staining, osteophyte formation of
connective tissue with mild subchondral bone plate
thickening (Figure 11c). Histopathologic scores were 16,
16, and 18 respectively.
On the other hand, treated joints showed diffuse
hypercellularity, chondrocyte clusters, more calcification
and less erosion (Figure 11d). Histopathologic scores
were 11, 12, and 13 respectively.
Group-II
Post- injection termination after 1 month
The control joints show irregular surfaces; fissures,
markedly reduced extracellular matrix, and osteophytic-
formation.Histopathologic scores were 9, 10, and 10
respectively (Figure 12a).
Table 3 Mean values of the lameness scoring before and
after treatment for all groups at 1, 2, 6 months from the
treatment
Assessment time Group-I Group-II Group-III
Before Treatment 23 5
RLRLR L
1 month After Treatment 22335 5
2 month After Treatment 12224 5
6 month After Treatment 01124 4
R: right joint; L: left joint.
Figure 5 Anterio-posterior radiographic image of the carpal joint, showing different arthritic changes in the untreated joints
manifested by mild, moderate and severe narrowing of the joint spaces at (a) 1 month, (b) 2 month and (c) 6 month respectively,
post injection of Amphotericin-B.
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destruction, osteophyte formation, and subchondral
sclerosis were all reduced compared with that in the
control joints indicating that there was slow progression
of the O.A. changes (Figure 12b). Histopathologic scores
were 7, 8, and 8 respectively.
Post- injection termination after 2 months
The control joints treated with hyaluronic acid injection
showed substantial fibrillation of the articular surface
with loss of extracellular matrix, as well as large areas of
osteophytic formation (Figure 12c). Histopathologic
scores were 14, 14, and 15 respectively.
In the cell-treated joints, findings were better compared
to this group with less severe arthritic changes. Histopatho-
logic scores were 10, 11, and 11 respectively (Figure 12d).
Post-injection termination after 6 months
There were significant OA lesions in both the cell-trea-
ted and control joints. Histopathologic scores for control
Figure 6 Latro-medial radiographic image of the carpal joint, showing Different arthritic changes manifested by mild, moderate and
severe narrowing of the joint spaces at (a) 1 month, (b) 2 month and (c) 6 month respectively, post injection of Amphotericin-B.
Figure 7 Flexed radiographic image of the carpal joint of group-III, showing the cartilage at (a) 1 month, (b) 2 month and (c) 6 month
post injection of Amphotericin-B . Notice the thining of the articular cartilage compared to treated carpal joints -images on the right- at (d) 1
month, (e) 2 month and (f) 6 month post treatment with MSCs. Compare arrow with its contralateral.
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Page 8 of 18group were 17, 18, and 18 (Figure 12e) while for the
cell-treated group were 14, 14, and 15 respectively (Fig-
ure 12f).
Group-III
Control cases in all subgroups showed marked OA
changes in the form of erosions, pannus bone eburna-
tion, osteophytic formation, loss of matrix staining,
moderate to severe subchondral plate thickening (Figure
13a, c, and 13e). Histopathologic scores ranged from 15
to 19.
Cell-treated joints show nearly the same findings with
slight difference or improvement of the articular carti-
lage status (Figure 13b, d and 13f). Histopathologic
scores ranged from 11 to 18.
In all groups with different follow up periods there
was significant difference between MSCs-treated cases
and control cases (P- value < 0.05) (table 6).
Discussion
Several tissue-engineering approaches have been used
for the repair of joint lesions. Techniques that cause
multipotent adult mesenchymal stem cells (MSCs) to
differentiate into cells of the chondrogenic lineage have
led to a variety of experimental strategies. In certain
joint degenerative diseases such as osteoarthritis (OA),
stem cells are depleted and have reduced proliferative
capacity and reduced ability to differentiate [31]. The
systemic or local delivery of stem cells to these indivi-
duals may therefore enhance repair or inhibit the pro-
gressive loss of joint tissue [20]. This study evaluated
the effect of stem cell therapy suspended in hyaluronic
acid for repair or delaying the progression of arthritic
lesions that occur following joint injury and compared it
to the use of hyaluronic acid alone.
Amphotericin-B was used in this work for induction
of arthritis. Efficacy of Amphotericin-B in arthritis
induction was reported in a previous work [14]. Chemi-
cal induction of OA when compared to surgical meth-
o d si sa ne a s y ,r a p i da n dl e s si n v a s i v et e c h n i q u e[ 3 2 ] .
Intra-articular injection of Amphotericin-B is an effec-
tive method to induce a synovitis/arthritis model and
lameness in cattle. The histopathological degenerative
changes that were obtained in this study by chemical
induction was found to be comparable with the findings
described [33] who used the surgical method for OA
induction in the knee joint of rats.
Clinically, the immediate lameness after amphotericin
B injection and joint swelling could be attributed to the
initiation of an inflammatory process that caused synovi-
tis and capsulitis. This can be due to the toxic effect of
Amphotericin-B on the cartilage matrix as well as the
synovial and capsular membranes with subsequent
increase of synovial production [34]. Amphotericin-B
has a direct toxic effect on chondrocyte resulting in the
commencement of osteoarthritic changes in the injected
joint [10]. In the study the lameness were more intense
in group-III (score 5) than the other two groups. When
treatment started, the degree of improvement depended
mainly on the initial degree of severity of the condition,
hence group-I showed better mending, (score 0 after 6
months of treatment), than the other two groups. Evi-
dences of arthritic changes in the form of joint swelling
and joint capsular distention were sighted, also radiogra-
phically, in all animals injected with Amphotericin-B in
group-II and III. No visible radiographic signs of neither
bone lysis nor osteophyte formation was seen in animals
of group-I. Moderate and severe arthritic changes were
observed in group-II group-III consequently. The sever-
ity of the alteration was in direct relationship to the
Table 4 Mean value of the radiographic scoring of
osteophytes formation and cartilage loss of different
groups; before and at 1, 2, 6 months from the treatment
Assessment time Group-I Group-II Group-III
Before Treatment 0(2) 2(3) 4(4)
RLRLR L
1 month After Treatment 00234 4
2 month After Treatment 00134 4
6 month After Treatment 00123 4
R: right joint; L: left joint; (Values between brackets) indicate score of cartilage
loss.
Table 5 Summary of the biochemical characteristics of
synovial fluid analysis (Mean +/-SD)
TP AST ALT ALK LDH
Control 1.56 ±
0.06
15.33 ±
2.76
6 ± 2 12 ± 2.0 36.5 ± 11.5
3
weeks
3.56 ±
0.04
38 ± 4.0 42.66 ±
6.6
57 ± 5.0 136.66 ± 8.6
6
weeks
3.58 ±
0.38
64.66 ± 4.4 75.33 ±
5.3
92.66 ± 4.6 256.66 ±
16.6
9
weeks
4.66 ± 0.4 82.66 ± 2.4 88 ± 4.0 133.33 ±
2.6
435.33 ±
20.0
TP: total proteins; AST: aspartate aminotransferase; ALT: Alanine
aminotransferase; ALK: alkaline phosphatase; and LDH: Lactic acid
dehydrogenase.
Table 6 Summary of Total proteins values in all 3 groups
at different stages of the experiment
Total protein Group-I Group-II Group-III
Control 1.56 1.56 1.56
pre treatment 3.56 3.58 4.66
1 month post treatment 1.91 (2.21) 1.61 (2.11) 1.73 (4.12)
2 month post treatment 1.65 (2.43) 1.66 (2.56) 1.88 (4.51)
6month post treatment 1.6 (2.66) 1.73 (2.93) 1.99 (5.16)
(Values between brackets) indicate values of non-cell treated animals; left
joints.
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Page 9 of 18induction period of arthritis similar to the results
reported by (35, 8, and 10). Macroscopically, the differ-
ent magnitudes of the articular damage could be insinu-
ated as a result of the harmful effect of the injected
Amphotericin-B. It is stated that Amphotericin-B causes
lysosomal damage with liberation of its contents in the
joint compartment. This observation resembles the tis-
sue reaction in ponies using filipins (34, 8). As a result
Figure 8 Histograms showing physical, cytological and biochemical characteristics of synovial fluid analysis of the control and
experimental groups.
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Page 10 of 18of the alteration in the articular surface nature, osteo-
phyes starts to build-up cause the roughness in severe
cases as seen in cases of group-III.
In this study, and agreed with other literatures, it was
anticipated that established equine MSCs cultures would
be negative for CD34, and positive for CD29 [36]. Cells
were also characterized by their abilities to differentiate
into chondrocytes and osteocytes. In this study, the abil-
ity of GFP transfected mesenchymal stem cells to be
easily detected and its longevity enhanced our
hypothesis for successful homing. Because the cells used
in the present study were retrovirally transduced to
express GFP, it is conceivable that expressed GFP or the
vector used for the transduction may have affected the
outcome. However, transduction of the cells did not
affect their capacity to proliferate, and engraftment of
the transduced cells in the articular cartilage occurred
w i t h o u te v i d e n c eo fa ni m m u n er e s p o n s ea tt h i ss i t eo r
elsewhere in the joint. The same conclusion was
reported by [20].
Figure 9 (a) left antebrachiocarpal joint after 9 weeks of OA induction and 6 month of no treatment showing severe articular surface
degeneration affecting the 1: ulnar carpal bone, 2: intermediate carpal bone and 3: radial carpal bone. Notice the degenerative line
marked by the arrow; (b) right antebrachiocarpal joint after 9 weeks of OA induction and 6 month of MSCs treatment showing improved
articular surface. Notice the partial degenerative areas marked by the arrows; (c) left untreated joint of group-I after 2 month follow-up and (d)
right treated joint; (e) untreated joint of group-II after 6 month follow-up (f) treated joints. Arrows indicates areas of degeneration. Compare left
images (non-cell-treated) with the contralateral (cell-treated) ones.
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Page 11 of 18Homing was proved in all injected specimens after 1,
2, and 6 months of follow up as GFP-labeled injected
MSCs were detected in all examined articular cartilages.
Some cells exhibited a chondrocyte-like phenotype
(rounded form; surrounded by a lacuna) indicating dif-
ferentiation of injected MSCs while in other areas cells
remained spindle-like (mesenchymal). Thus we can
propose that the local environment of the homing site
can induce a chondrogenic phenotype in undifferen-
tiated MSCs [37].
Previous study showed that implanted PKH 26-labeled
MSCs were identified in the newly formed bony trabe-
culae in specimens at 2 and 4 months after implanta-
tion. These results offer a potential approach to meet
Figure 10 Fluorescence microscopic analysis of the cell-treated joints showing GFP-positive cells detected at the surface and also in
the center of regenerated tissue in all groups. Group-I; (a) at 2 months and (b) at 6 month after injection of GFP-transduced MSCs. Group-II;
show diffuse hypercellularity after 2 months (c) and clusters of chondrocytes after 6 months of injection (d). Group-III; show slight hypercellularity
after 2 month (e) with clusters of chondrocytes (short arrow) and multiple tide marks (long arrow) after 6 months of injection (f).
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Page 12 of 18clinical requirements in the treatment of infected bone
defects [38].
A n o t h e rp r e v i o u ss t u d yw a sc o m p a r e dt h ein vivo
chondrogenic potential of synovial MSCs, bone mar-
row MSCs, adipose MSCs, and muscle MSCs by trans-
planting them into cartilage defects in rabbits. Synovial
MSCs and bone marrow MSCs had much more chon-
drogenic potential than adipose MSCs and muscle
MSCs [39].
In this study, MSCs were suspended in sodium hyalur-
onate before injection and control joints were injected
by sodium hyaluronate only. As regards the control
joints, the histological findings reflected the degenerative
nature of this model as presence of surface cartilage
irregularities and fibrillation, edema, hypocellularity
alternating with hypercellular & proliferative areas and
decrease of the concentration of proteoglycans charac-
terized by the reduction of staining intensity. Such
changes are observed in the DJD and were also
described by [40,41].
The absence of obvious beneficial effect of the sodium
hyaluronate alone on the structure of the degenerate
articular cartilage was evident by histological scores.
Comparable results were described by [42-44].
The presence of proliferation of chondrocytes may be
explained as the injury to the structure of the cartilage
produced death of the chondrocytes and initiated a
repair response, resulting in chondrocyte proliferation.
Sandell and Aigner in 2001 [45] have described similar
changes of the articular cartilage to counteract losses
occurred during DJD, by the increase of chondrocyte
proliferative activity.
Some authors [46,47] reported that hyaluronan contri-
butes to the granulation phase of wound healing and sti-
mulates the migration and mitosis of mesenchymal and
epithelial cells. So, MSC-based repair in the presence of
hyaluronan may therefore accelerate and amplify the
natural repair process of recruiting these cells to the site
of tissue repair or regeneration.
The involvement of injected MSC in the development
of appreciable neocartilagenous tissue in treated joints
was associated with protection against more severe
degenerative changes when compared with control
joints. However, the continuing degradation of treated
joints that occurred at prolonged time points indicate
the need for some augmentation of natural repair by
MSCs. This is evidenced by the histopathologic scoring
of different groups where the score of MSCs-treated
cases in group-I after 2 months follow up were 7, 8, and
8 and in control joints were 9, 10, and 10 while after 6
months follow up the scores were 12, 13, 13 and in con-
trol joints were 16, 16, and 18 respectively. Other evi-
dence could be noticed by comparison of the previous
results with that of group-III after 6 months follow up
period where score of MSCs-treated cases were 17, 17,
18 and in control joints were 19 in all cases denoting
that Cell-treated joints show slight difference or
improvement of the articular cartilage status.
It was noticed that the mean histopathological scores
of the stem cell treated group was smaller than the con-
trol group mean score in the 3 studied groups. It
reflected the presence of less conspicuous degenerative
injuries, assuming that mesenchymal stem cells stimu-
lated the reparative process or delayed the disease evolu-
tion. The difference among the treated groups and
control ones was significant (P < 0.05). This beneficial
effect on the degenerate cartilage was also described by
[20].
The best effect of MSCs on different degrees of arthri-
tis was not clearly concluded from our results except
that the effect in group-III was minimal. Also, the grad-
ing scores in the treated cases in group-II were greater
than those of group-I. It is likely that the cumulative
effect of the abnormal load imposed as a result of the
severed cartilage resulted in progressive cartilage
damage that was not completely prevented by the repair
process. So we concluded that the earlier the injection
the better the effect. However, these results should be
applied on large number of animals for better
evaluation.
Conclusion
Augmented therapeutic effect was proved with intra-
articular injection of stem cells suspended in hyaluronic
acid than the injection of hyaluronic acid alone follow-
ing injury of the joint. This injection offers repair of
affected joint and reduction or delay in the progression
to OA. Earlier injection of MSCs is more beneficial.
We are dealing with progressive degenerative disease
and our results show that the animal score deteriorate
by time. MSC only delay this deterioration but doesn’t
improve it totally so we may need repeated injections to
reach better results. Although this study had a follow up
Table 7 Statistical significance of all treated groups at
different follow up periods
Group/follow up
period
Control
Median &
(Q1, Q3)*
Cases
Median &
(Q1, Q3)*
P- value
Group-I: 2months 10, (9, 10) 8, (7, 8) 0.043
6 months 16, (16, 18) 13, (12, 13) 0.043
Group-II: 1 month 10, (9, 10) 6, (5, 6) 0.043
2 months 14, (14, 15) 11, (10, 11) 0.043
6 months 18, (17, 18) 15, (14, 15) 0.043
Group-III: 1 month 15, (14, 15) 12, (11, 13) 0.046
2 months 17, (16, 17) 14, (14, 15) 0.043
6 months 19, (19, 19) 17, (17, 18) 0.034
*Q1 = 1
st quartile or 25
th percentile Q3 = 3
rd quartile or 75
th percentile
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Page 13 of 18Figure 11 Articular cartilage of group-I two months post injection: (a) control joint showing degenerative changes in the form of
hypocellularity, fibrillation (arrow) & fissures (dotted arrows) (H&E 200X); (b) MSCs treated joint showing regenerative changes in
articular cartilage including diffuse hypercellularity chondrocyte clones (arrows), regular surface and moderate decrease in matrix
staining in superficial and middle zones (Alcian blue-PAS 100X). Articular cartilage of group-I six months post injection: (c): control joint
showing duplicated tide marks (arrows) and moderate thickening of subchondral bone plate (H&E 100X); (d) MSCs treated joints showing
regenerative changes in the form of moderate decrease of staining intensity of extracellular matrix with hypercllularity (MT 100X).
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Page 14 of 18Figure 12 Articular cartilage of group-II one month post injection: (a) control joint showing superficial fibrillation & clefts involving 1/
3 with slight hypocellularity (H&E 100X); (b): MSCs-treated joint showing hypercellularity and marked decrease in staining with focal
areas showing synthesis of extracellular matrix (arrows) (MT 100x). Articular cartilage of group-II two months post injection: (c) control joint
showing irregular surface with superficial fibrillation & clefts involving up to 2/3 with slight hypercellularity and moderate subchondral bone
thickening (H&E 100x); (d)MSCs, treated joint showing regenerative changes in articular cartilage with slight hypercellularity and increased matrix
synthesis (arrows) in lower zone (Alcian blue-PAS 100x). Articular cartilage of group-II six months post injection: (e) control joint showing near
total replacement of articular cartilage with fibrous tissue, loss of chondrocytes and marked subchondral bone thickening (H&E 100x); (f) MSCs-
treated joint showing degenerative changes in the form of irregular surface, fissures and hypocellularity in superficial & middle zone and
regenerative changes in lower zone denoted by increased matrix synthesis (arrows) (Alcian blue-PAS 100x).
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Page 15 of 18Figure 13 Articular cartilage of group-III one month post injection: (a) control joint showing surface irregularity with hypocellularity
and marked multiple tide marks (H&E 100x); (b) MSCs- treated joint showing degenerative changes with irregular surface, erosion
(arrow) and hypocellularity in superficial zone and regenerative changes in middle zone & lower zone denoted by increased matrix
synthesis, slight hypercellularity and chondrocytes clones (Alcian blue-PAS 100x). Articular cartilage of group-III two months post injection:
(c) control joint showing surface erosion of articular cartilage with superficial loss of chondrocytes and moderate hypercellularity of rest of
cartilage (H&E 100x); (d) MSCs-treated joint showing degenerative changes in the form of irregular surface, hypocellularity in superficial & middle
zone and regenerative changes in lower zone denoted by hypercellularity& increased matrix synthesis (Alcian blue-PAS 100x). Articular cartilage
of group-III six months post injection: (e) control joint showing articular cartilage destruction, pannus formation (arrow) and marked subchondral
plate thickening (H&E 100x); (f) MSCs-treated joint showing articular cartilage destruction, fibrous tissue, scattered atrophic chondrocytes and
marked subchondral plate thickening (H&E 100x).
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Page 16 of 18period of 6 months, longer term follow up is mandatory
to study the permanency of the effect and fate of
injected cells.
Abbreviation
MSC: Mesenchymal stem cell; GFP: Green fluroscent
protein; I.A.: Intra-aticularily; O.A.: Osteoarthritis;
DPBS: Dulbecco’s phosphate-buffered saline; BMP-2:
Bone morphogenetic protein-2; TGF ß3: Transforming
growth factor ß3; APA: American Psychological Asso-
ciation; MT: Masson’s trichrome; H&E: Haematoxy-
lene and eosin; SPSS: Statistical package for social
science.
Additional material
Additional file 1: All groups of animals’ data sheet format of the
present work of the study. Timetable sheet format provided showing
aspiration of the synovial fluid and at the same procedure; each animals
received its designated autologous MSCs IA injection coupled with
hyaluronic acid on its right carpal joint, while the left carpal joint was
injected with hyaluronic acid only.
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